Business Standard

A COMMERCIAL FEATURE

What's this ?

Commercial Feature is a Business Standard Digital Marketing Initiative.

The Editorial/Content team at Business Standard has not contributed to writing or editing these articles.

For further information, please write to assist@bsmail.in

DCGI grants approval for AstraZeneca's inhaler to treat asthma

Symbicort Turbuhaler contains two active ingredients in one inhaler - budesonide and formoterol

BS B2B Bureau  |  Mumbai 

Ashtma patient image via Shutterstock
Image via Shutterstock

Pharma India Ltd has received the approval of Drug Controller General of India (DCGI) for marketing its drug in the country. The product contains two active ingredients in one inhaler - (320 µg) and (9 µg). 

Pharma India Limited has received import and market permission in Form 45 (Marketing Authorization) from the Drug Controller General of India for FDC (fixed dosage combination) of and fumarate dihydrate inhalation powder,” said BSE on June 15, 2017.

Symbicort Turbuhaler, a product of global, is indicated in the regular treatment of where use of combination of inhaled regular corticosteroid & long acting beta-agonist is appropriate and patients with moderate to severe COPD (chronic obstructive pulmonary disease) with frequent symptoms and a history of exacerbations.

RECOMMENDED FOR YOU

DCGI grants approval for AstraZeneca's inhaler to treat asthma

Symbicort Turbuhaler contains two active ingredients in one inhaler - budesonide and formoterol

Symbicort Turbuhaler contains two active ingredients in one inhaler - budesonide and formoterol
Pharma India Ltd has received the approval of Drug Controller General of India (DCGI) for marketing its drug in the country. The product contains two active ingredients in one inhaler - (320 µg) and (9 µg). 

Pharma India Limited has received import and market permission in Form 45 (Marketing Authorization) from the Drug Controller General of India for FDC (fixed dosage combination) of and fumarate dihydrate inhalation powder,” said BSE on June 15, 2017.

Symbicort Turbuhaler, a product of global, is indicated in the regular treatment of where use of combination of inhaled regular corticosteroid & long acting beta-agonist is appropriate and patients with moderate to severe COPD (chronic obstructive pulmonary disease) with frequent symptoms and a history of exacerbations.

image
Business Standard
177 22

DCGI grants approval for AstraZeneca's inhaler to treat asthma

Symbicort Turbuhaler contains two active ingredients in one inhaler - budesonide and formoterol

Pharma India Ltd has received the approval of Drug Controller General of India (DCGI) for marketing its drug in the country. The product contains two active ingredients in one inhaler - (320 µg) and (9 µg). 

Pharma India Limited has received import and market permission in Form 45 (Marketing Authorization) from the Drug Controller General of India for FDC (fixed dosage combination) of and fumarate dihydrate inhalation powder,” said BSE on June 15, 2017.

Symbicort Turbuhaler, a product of global, is indicated in the regular treatment of where use of combination of inhaled regular corticosteroid & long acting beta-agonist is appropriate and patients with moderate to severe COPD (chronic obstructive pulmonary disease) with frequent symptoms and a history of exacerbations.

image
Business Standard
177 22